Literature DB >> 31041504

Indications for bone marrow examinations in rheumatology.

Hava Üsküdar Teke1, Döndü Üsküdar Cansu2, Cengiz Korkmaz3.   

Abstract

Hematologic involvement or hematologic malignancies are frequently encountered during the course of rheumatic diseases. Bone marrow (BM) aspiration and/or biopsy examinations may have a diagnostic role in explaining hematologic findings detected in rheumatology clinical practice. Our aim was to describe the indications for BM examinations and to share our BM aspiration/biopsy results. We analyzed 140 BM aspiration/biopsy results of patients conducted at the Department of Rheumatology from 2010 to 2018. Demographics, complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) values, serum biochemistry test results including lactate dehydrogenase (LDH), organomegaly, indications for BM examinations and BM examination results for each patient, and mortality rates were recorded. Out of the 140 patients, 63.6% were female, and the median (Q1-Q3) age was 53 (39.5-65) years. One hundred fifteen (82.1%) patients were diagnosed as having primary rheumatic disease, and 25 (17.8%) were admitted due to musculoskeletal symptoms. Rheumatoid arthritis (RA) (n = 34, [29.5%]), and systemic lupus erythematosus (SLE) (n = 21, [18.2%]) were the most common rheumatic diseases. Cytopenia was the most common indication for BM aspiration/biopsy (n = 83, [59.3%]). Thirty-nine (47%) of 83 patients had drug-induced cytopenia. A pathology was detected in 40 (28.5%) of the 140 BM examinations. Patients with pathologic BM results had either a hematologic malignancy (n = 38, [95%]) or metastasis to a solid organ (n = 2, [5%]). The group of patients with pathologic BM biopsy results had significantly higher rates of lymphadenopathy, splenomegaly, and monoclonal gammopathy compared with the group with non-pathologic results (p = 0.001, p = 0.011, and p = 0.023, respectively). Likewise, LDH concentrations of those with pathologic results were higher than in patients with non-pathologic results [737 (range 577-1420) IU/L vs. 541 (range 306-840) IU/L, p = 0.019]. In this study, cytopenia or CBC abnormalities accompanied by elevated LDH values or anemia along with increased ESR were the most common indications for BM aspiration/biopsy. Further prospective studies are needed to determine the indications of BM aspiration/biopsy and establish the parameters that predict abnormal BM results in rheumatology practice.

Entities:  

Keywords:  Bone marrow examination; Cytopenia; Rheumatology

Mesh:

Year:  2019        PMID: 31041504     DOI: 10.1007/s00296-019-04312-w

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  15 in total

1.  Bone marrow findings in connective tissue disease.

Authors:  N S Rosenthal; D C Farhi
Journal:  Am J Clin Pathol       Date:  1989-11       Impact factor: 2.493

2.  Prevalence and long-term significance of paraproteinaemia in rheumatoid arthritis.

Authors:  M J Garton; G Keir; A Dickie; M Steven; J A N Rennie
Journal:  Rheumatology (Oxford)       Date:  2006-02-01       Impact factor: 7.580

3.  Morbidity associated with bone marrow aspiration and trephine biopsy - a review of UK data for 2004.

Authors:  Barbara J Bain
Journal:  Haematologica       Date:  2006-09       Impact factor: 9.941

Review 4.  A reappraisal of the association between Behçet's disease, myelodysplastic syndrome and the presence of trisomy 8: a systematic literature review.

Authors:  Sinem Nihal Esatoglu; Gulen Hatemi; Ayse Salihoglu; Ibrahim Hatemi; Teoman Soysal; Aykut Ferhat Celik
Journal:  Clin Exp Rheumatol       Date:  2015-02-09       Impact factor: 4.473

5.  ICSH guidelines for the standardization of bone marrow specimens and reports.

Authors:  S-H Lee; W N Erber; A Porwit; M Tomonaga; L C Peterson
Journal:  Int J Lab Hematol       Date:  2008-10       Impact factor: 2.877

6.  Clinical interest of bone marrow aspiration in rheumatology: a practice-based observational study of 257 bone marrow aspirations.

Authors:  Amélie Loctin; François Bailly; Davy Laroche; Christian Tavernier; Jean-Francis Maillefert; Paul Ornetti
Journal:  Clin Rheumatol       Date:  2012-10-02       Impact factor: 2.980

7.  [Rationale for bone marrow examination in patients with inflammatory rheumatic diseases].

Authors:  Jutta G Richter; Pascal Gossen; Ulrich Germing; Sabine Blum; Barbara Hildebrandt; Stefan Braunstein; Dörte Huscher; Matthias Schneider
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

Review 8.  Non-chemotherapy drug-induced neutropenia: key points to manage the challenges.

Authors:  Brian R Curtis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 9.  Macrophage activation syndrome in the era of biologic therapy.

Authors:  Alexei A Grom; AnnaCarin Horne; Fabrizio De Benedetti
Journal:  Nat Rev Rheumatol       Date:  2016-03-24       Impact factor: 20.543

Review 10.  Hematological malignancies mimicking rheumatic syndromes: case series and review of the literature.

Authors:  Gil Bornstein; Nadav Furie; Nimrod Perel; Ilan Ben-Zvi; Chagai Grossman
Journal:  Rheumatol Int       Date:  2018-07-18       Impact factor: 3.580

View more
  1 in total

1.  Dual-Energy Computed Tomography-Based Quantitative Bone Marrow Imaging in Non-Hematooncological Subjects: Associations with Age, Gender and Other Variables.

Authors:  Florian Hagen; Jan Fritz; Antonia Mair; Marius Horger; Malte N Bongers
Journal:  J Clin Med       Date:  2022-07-14       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.